Evidence map›Paper›PMID 38172635›Full record

ArticleNature2024

A new antibiotic traps lipopolysaccharide in its intermembrane transporter.

Karanbir S Pahil, Morgan S A Gilman, Vadim Baidin, Thomas Clairfeuille, Patrizio Mattei, Christoph Bieniossek, Fabian Dey, Dieter Muri, Remo Baettig, Michael Lobritz and 3 more

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
23.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Rapid delineation ofMicrobiology spectrum · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Ciprofloxacin resistance enhances biofilm formation and modulates virulence in Acinetobacter baumannii: Insights into the role of efflux pumps and quorum sensing.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Karanbir S Pahil *Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0003-0247-5934
Morgan S A Gilman *Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
Vadim BaidinDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA.ORCID 0000-0002-6257-1226
Thomas ClairfeuilleDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Patrizio MatteiDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0002-2217-8833
Christoph BieniossekDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Fabian DeyDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0002-4903-2869
Dieter MuriDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0002-7617-9364
Remo BaettigDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Michael LobritzDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Kenneth BradleyDepartments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.ORCID 0000-0002-4757-5122
Andrew C KruseDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. Andrew_Kruse@hms.harvard.edu.ORCID 0000-0002-1467-1222
Daniel KahneDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA, USA. kahne@chemistry.harvard.edu.ORCID 0000-0002-8296-1424
Roche (Switzerland) · CHHarvard University · US

Funding

Project 3: Defining and defeating the mechanisms of outer membrane biogenesis in Gram-negative bacteriaU19AI158028 · NIAID · HARVARD MEDICAL SCHOOL · PI WALKER, SUZANNE · 2022 to 2025
$10.1M
Outer Membrane Biogenesis: New Antibiotic TargetsR01AI081059 · NIAID · HARVARD UNIVERSITY · PI Daniel Kahne · 2009 to 2026
$9.5M
Studies on the Biological Mechanisms of AntibioticsR01AI149778 · NIAID · HARVARD UNIVERSITY · PI Daniel Kahne · 2020 to 2026
$4.7M
Targeting Membrane Transport Steps in Cell Envelope AssemblyR01AI153358 · NIAID · HARVARD UNIVERSITY · PI KAHNE, DANIEL, KRUSE, ANDREW · 2020 to 2024
$3.6M
NIAID NIH HHS R01 AI081059NIAID NIH HHS R01 AI149778NIAID NIH HHS R01 AI153358NIAID NIH HHS U19 AI158028
6 · The paper itself

Abstract

Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet

Indexed as

Anti-Bacterial AgentsBacterial Outer Membrane ProteinsLipopolysaccharidesMembrane Transport ProteinsAcinetobacterBinding SitesBiological TransportCell MembraneMicrobial ViabilityProtein ConformationSubstrate SpecificityAnti-Bacterial AgentsBacterial Outer Membrane ProteinsLipopolysaccharidesMembrane Transport Proteins

Identifiers

PMID38172635
PMCPMC10794137
OpenAlexW4390535733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.